Today I’m looking at two controversial and rather battered FTSE 100 stocks. I believe the outlook for each company may not be what you might expect, given recent news.
The first share under consideration is £32bn pharma group Shire (LSE: SHP). Chief executive Flemming Ornskov has never been short of ambition for his firm, and last year he went all out with a $32bn deal to acquire US firm Baxalta.
The benefits of this deal are now starting to appear. In its third-quarter results on Friday, the group reported a 20% increase in adjusted earnings, which rose to $3.81. This corresponded to a 20% increase in adjusted net profit, which rose to $1,158m.
Highlights from the quarter included a 32% increase in sales of immunology medicines, compared to the same period last year. This helped to offset the effects of weaker demand for genetic treatments.
The group’s financial performance has certainly improved this year. Net cash generated by operating activities doubled to $1,055m during the quarter, helping Shire to reduce its net debt by a further $920m.
With nine months of the year complete, management has left its guidance for the full year unchanged. Based on broker forecasts, this suggests that the stock trades on a forecast P/E of 9.3 for 2017.
This may seem cheap, but it’s worth remembering that the group’s net debt of $20.4bn makes the stock significantly more expensive than the P/E ratio suggests.
An alternative valuation measure I like to use is earnings yield, which compares operating profit with enterprise value (market cap plus net debt). I estimate Shire’s earnings yield at about 3.5%, but I normally prefer to invest in stocks with an earnings yield of at least 8%.
In my view, it’s probably too soon to check back into Shire.
Shopping for a bargain?
High street stalwart Marks and Spencer Group (LSE: MKS) is seriously out of fashion at the moment. But the group’s food business is growing steadily, and selling clothes still generates a lot of cash.
Indeed, the group’s shares currently trade on a trailing price/free cash flow ratio of just 8.6, which is very cheap if it’s sustainable. The evidence so far is that this cash generation can be sustained.
Indeed, the firm’s adjusted earnings are expected to bottom out at 27.9p per share this year, before climbing to 28.5p in 2018/19. This puts the stock on a reasonable forecast P/E of 12.4. It also provides a decent level of cover for the expected dividend payout of 18.7p per share, which implies a yield of 5.4% at the share price of 345p.
I’m starting to be get interested in M&S, as I think the group’s Food business should continue to offset a slower recovery in the clothing and home divisions. The first-quarter figures published in the summer seem to support this view — Clothing & Home revenue fell by 0.5%, but Food sales rose by 4.5%.
The business is being reshaped to provide more space for Simply Food, and to improve the stores’ integration with the group’s online sales channels. This seems logical to me and although it’s too soon to be certain, I believe now might be a good time to buy into the turnaround.
Markets around the world are reeling from the coronavirus pandemic…
And with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.
But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be daunting prospect during such unprecedented times.
Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…
You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.
That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.
Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.